Determination of CYP2D6 gene copy number by pyrosequencing

Clinical Chemistry

Volumn 51, Issue 3, 2005, Pages 522-531

  Söderbäck, Erik ^a,c   Zackrisson, Anna Lena ^b   Lindblom, Bertil ^b   Alderborn, Anders ^a  

^a BIOTAGE AB   (Sweden)

^b National Board of Forensic Medicine   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE SEQUENCE; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PSEUDOGENE; PYROSEQUENCING; REPRODUCIBILITY; TEMPERATURE;

BASE SEQUENCE; CYTOCHROME P-450 CYP2D6; GENE DOSAGE; HUMANS; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SEQUENCE ALIGNMENT;

EID: 14544294868     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.043182     Document Type: Article

References (36)

1. Online Mendelian Inheritance in Man (OMIM) http://www.ncbi.nlm.nih.gov/ entrez/Omim (accessed May 24, 2004).
2. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989;45:889-904.
3. Bertilsson L, Dahl M-L, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22.
4. Home Page of the Human Cytochrome P450 (CVP) Allele Nomenclature Committee.CYP2D6 allele nomenclature. http://www.imm.ki.se/CYPalleles/cyp2d6.htm (accessed May 24, 2004).
5. Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992;14:49-58
6. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825-9.
7. Hersberger M, Marti-Jaun J, Rentsch K, Hänseier E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000;46:1072-7.
8. Dalen P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998;63:444-52.
9. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.
10. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999;147:300-5.
11. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441-6.
12. Johansson I, Lundqvist E, Dahl M-L, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996;6:351-5.
13. Neville M, Selzer R, Aizenstein B, Maguire M, Hogan K, Walton R, et al. Characterization of cytochrome P450 2D6 alleles using the Invader system. Biotechniques 2002;32:S34-S43.
14. Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 2003;22:476-85.
15. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998;281:363, 365.
16. Berg LM, Sanders R, Alderborn A. Pyrosequencing technology and the need for versatile solutions in molecular clinical research [Review]. Expert Rev Mol Diagn 2002;2:361-9.
17. Ahmadian A, Gharizadeh B, Gustafsson AC, Sterky F, Nyren P, Uhlen M, et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem 2000;280:103-10.
18. Alderborn A, Kristofferson A, Hammerling U. Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing. Genome Res 2000;10:1249-58.
19. Garcia CA, Ahmadian A, Gharizadeh B, Lundeberg J, Ronaghi M, Nyren P. Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene. Gene 2000;253:249-57.
20. Goriely A, McVean GA, Rojmyr M, Ingemarsson B, Wilkie AO. Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line. Science 2003;301:643-6.
21. Jonasson J, Olofsson M, Monstein HJ. Classification, identification and subtyping of bacteria based on Pyrosequencing and signature matching of 16S rDNA fragments. APMIS 2002;110:263-72.
22. Rahim A, Coutelle C, Harbottle R. High-throughput Pyrosequencing of a phage display library for the identification of enriched target-specific peptides. Biotechniques 2003;735:317-24.
23. Gruber JD, Colligan PB, Wolford JK. Estimation of single nucleotide polymorphism allele frequency in DNA pools using Pyrosequencing. Hum Genet 2002;110:395-401.
24. Neve B, Froguel P, Corset L, Vaillant E, Vatin V, Boutin P. Rapid SNP allele frequency determination in genomic DNA pools by Pyrosequencing. Biotechniques 2002;32:1138-42.
25. Lavebratt C, Sengul S, Jansson M, Schalling M. Pyrosequencing-based SNP allele frequency estimation in DNA pools. Hum Mutat 2004;23:92-7.
26. Tost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 2003;35:152-6.
27. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003;35:146-50.
28. Eriksson S, Berg L, Wadelius M, Alderborn A. Cytochrome P450 genotyping by multiplexed real-time DNA sequencing with Pyrosequencing technology. Assay Drug Dev Technol 2002;1:49-59.
29. Zackrisson AL, Lindblom B. Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur J Clin Pharmacol 2003;59:521-6.
30. Wadelius M, Sorlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004;4:40-8.
31. Furman KD, Grimm DR, Mueller T, Holley-Shanks RR, Bertz RJ, Williams LA, et al. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 2004;14:279-84.
32. Min DI, Ellingrod VL, Marsh S, McLeod H. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2004;26:524-8.
33. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 1991;11:298-300, 302.
34. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS 1996;392:30-4.
35. Jansson M, Rada A, Tomic L, Larsson L-I, Wadelius C. Analysis of the Glutathione S-transferase M1 gene using pyrosequencing and multiplex PCR - no evidence of association to glaucoma. Exp Eye Res 2003;77:239-43.
36. Pielberg G, Day AE, Plastow GS, Andersson L. A sensitive method for detecting variation in copy numbers of duplicated genes. Genome Res 2003;13:2171-7.